WallStSmart
CRDL

Cardiol Therapeutics Inc Class A

NASDAQ: CRDL · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC

$1.35
-3.48% today

Updated 2026-06-05

Market cap
$130.26M
P/E ratio
P/S ratio
1,014.87x
EPS (TTM)
$-0.28
Dividend yield
52W range
$1 – $2
Volume
0.7M

Cardiol Therapeutics Inc Class A (CRDL) Financial statements

SEC filings — annual and quarterly data.

Profit margin
0.00%
Operating margin
0.00%
ROE
-149.91%
ROA
-78.20%
Debt/equity
0.00x

Margin trends — annual

Gross margin Operating margin Profit margin
YearRevenueNet incomeGross marginOp. marginProfit margin
2017$-1.66M
2018$0.00$-15.89M
2019$0.00$-10.55M
2020$78760.00$-16.20M-228.76%-20,620.30%-20,570.94%
2021$62267.00$-25.01M-179.87%-49,092.44%-40,170.87%
2022$0.00$-22.82M
2023$0.00$-21.22M
2024$0.00$-36.68M
2025$0.00$-33.82M

Frequently asked questions

How much free cash flow does CRDL generate?

CRDL produced $-23.88M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is CRDL's balance sheet healthy?

CRDL holds $21.42M in cash and equivalents against — in long-term debt, on $17.88M of shareholder equity. That debt is best read against the cash flow the business throws off each year.